Does romiplostim have a boxed warning?

No. Unlike the erythropoiesis-stimulating agents it does not carry an ESA-style boxed warning, but it does have important risks including bone-marrow reticulin and thrombosis.

What happens if romiplostim is stopped?

Platelet counts can drop, sometimes below baseline (rebound thrombocytopenia), increasing bleeding risk, so platelets are monitored during and after treatment.

Is romiplostim used for low platelets from MDS?

No. It is not indicated for thrombocytopenia due to myelodysplastic syndrome, where TPO agonists have raised concerns about disease progression.

EMA-approvedaka Nplate, AMG 531

Romiplostim — Complete Research Guide (2026)

Q: How does romiplostim work?

It is a peptibody that activates the thrombopoietin receptor on megakaryocytes, increasing platelet production; it does not share sequence homology with natural thrombopoietin.

Last updated 2026-06-30

TL;DR

Romiplostim (also known as Nplate) is a peptide catalogued under Immune (TPO receptor agonist peptibody). It is described as: TPO receptor. Documented context: ITP. Neutral reference entry; EU status: EU-approved prescription medicine.

What is Romiplostim?

Romiplostim (Nplate) is a thrombopoietin (TPO) receptor agonist peptibody - an Fc-fusion protein carrying TPO-mimetic peptides that share no sequence homology with endogenous thrombopoietin. It is FDA- and EMA-approved and given by weekly subcutaneous injection.

It is approved for chronic immune thrombocytopenia (ITP) in adults (and children aged 1 year and older) with insufficient response to corticosteroids, immunoglobulins or splenectomy, and additionally for the haematopoietic subsyndrome of acute radiation syndrome. Its efficacy is supported by randomized controlled trials.

Unlike the erythropoiesis-stimulating agents, romiplostim does not carry an ESA-style boxed warning, but it has defined risks around bone-marrow reticulin and thrombosis.

How does Romiplostim work?

Romiplostim binds and activates the thrombopoietin receptor (c-Mpl) on megakaryocytes and their progenitors, driving megakaryocyte proliferation and differentiation and thereby increasing platelet production.

Because it raises platelet output rather than blocking platelet destruction, platelet counts fall again after the drug is stopped.

What does the research say about Romiplostim?

In the pivotal phase 3 randomized trials, romiplostim produced a durable platelet response in a significantly greater proportion of splenectomized and non-splenectomized chronic-ITP patients than placebo. ^[1]
Compared with standard of care in non-splenectomized ITP, romiplostim achieved higher rates of platelet response with less bleeding and fewer splenectomies and rescue treatments. ^[2]
The first controlled study of the molecule (AMG 531) showed dose-dependent increases in platelet counts in chronic ITP. ^[3]

Clinical research & studies

The references below are the primary sources cited throughout this guide. Each links directly to PubMed or the regulator. Where evidence is preclinical (animal or in-vitro), that is stated rather than implied.

[1] Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: a double-blind randomised controlled trial — Kuter DJ et al., Lancet 2008. (Pivotal phase 3 randomized controlled trial)
[2] Romiplostim or standard of care in patients with immune thrombocytopenia — Kuter DJ et al., The New England Journal of Medicine 2010. (Randomized controlled trial)
[3] AMG 531, a thrombopoiesis-stimulating protein, for chronic ITP — Bussel JB et al., The New England Journal of Medicine 2006. (Phase 1-2 randomized controlled trial)
[4] Evaluation of bone marrow reticulin formation in chronic immune thrombocytopenia patients treated with romiplostim — Kuter DJ et al., Blood 2009. (Prospective marrow evaluation)
[5] Safety and efficacy of long-term treatment with romiplostim in thrombocytopenic patients with chronic ITP — Bussel JB et al., Blood 2009. (Open-label long-term extension)
[6] Long-term treatment with romiplostim in patients with chronic immune thrombocytopenia: safety and efficacy — Kuter DJ et al., British Journal of Haematology 2013. (Long-term safety/efficacy study)

Dosing context

This is not medical advice or a usage recommendation. Dosing figures are reported research context only, cited from the published literature.

In approved use, romiplostim is titrated to the lowest weekly subcutaneous dose that maintains a platelet count adequate to reduce bleeding risk - not to normalize the platelet count - to limit thrombotic and reticulin risk.

This is context only, not medical advice; dosing is individualized against platelet counts by a prescriber.

Side effects & safety profile

Romiplostim can increase bone-marrow reticulin and, rarely, collagen fibrosis; a dedicated marrow study documented reticulin formation during treatment, so persistent blood-film abnormalities warrant a marrow examination. Because it raises platelet counts, it carries a risk of thrombotic and thromboembolic complications that is not strictly proportional to the platelet count.

Stopping romiplostim can cause worsening (rebound) thrombocytopenia below baseline with bleeding risk, so platelets must be monitored during and after therapy. Long-term studies support sustained efficacy but reinforce ongoing monitoring for reticulin and thrombosis.

Romiplostim is not indicated for thrombocytopenia due to myelodysplastic syndrome (MDS), where TPO agonists have raised concern about blast increase and disease progression.

Stacking & combinations

Romiplostim is used within managed ITP care alongside agents such as corticosteroids or immunoglobulins under specialist supervision; it is not a recreational stack compound.

Finding Romiplostim vendors

This is an independent, neutral directory — we sell nothing and route no purchases. Use it to read regulatory context and (where available) genuine, moderated vendor information for your country.

Choose your country

We never list placeholder vendors. Pick your country to see neutral regulatory context.

Browse the directory

User reviews

No reviews yet

Reviews appear here once submitted and moderated. An aggregate rating is shown only after at least 5 genuine reviews — we never fabricate ratings.

Frequently asked questions

It is FDA- and EMA-approved for chronic immune thrombocytopenia (ITP) in adults and children with inadequate response to other therapies, and for the haematopoietic subsyndrome of acute radiation syndrome.

References

[1] Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: a double-blind randomised controlled trial — Kuter DJ et al., Lancet 2008. PMID: 18242413. View sourceStudy: Pivotal phase 3 randomized controlled trialRomiplostim produced durable platelet responses in significantly more splenectomized and non-splenectomized chronic-ITP patients than placebo.
[2] Romiplostim or standard of care in patients with immune thrombocytopenia — Kuter DJ et al., The New England Journal of Medicine 2010. PMID: 21067381. View sourceStudy: Randomized controlled trialVersus standard of care, romiplostim raised platelet responses and reduced bleeding, splenectomy and treatment failure.
[3] AMG 531, a thrombopoiesis-stimulating protein, for chronic ITP — Bussel JB et al., The New England Journal of Medicine 2006. PMID: 17050891. View sourceStudy: Phase 1-2 randomized controlled trialAMG 531 (romiplostim) produced dose-dependent increases in platelet counts in chronic ITP.
[4] Evaluation of bone marrow reticulin formation in chronic immune thrombocytopenia patients treated with romiplostim — Kuter DJ et al., Blood 2009. PMID: 19671919. View sourceStudy: Prospective marrow evaluationRomiplostim treatment was associated with increased bone-marrow reticulin in some patients, informing monitoring guidance.
[5] Safety and efficacy of long-term treatment with romiplostim in thrombocytopenic patients with chronic ITP — Bussel JB et al., Blood 2009. PMID: 18981291. View sourceStudy: Open-label long-term extensionLong-term romiplostim maintained platelet responses with a manageable safety profile over extended treatment.
[6] Long-term treatment with romiplostim in patients with chronic immune thrombocytopenia: safety and efficacy — Kuter DJ et al., British Journal of Haematology 2013. PMID: 23432528. View sourceStudy: Long-term safety/efficacy studySustained platelet responses were observed over years, with continued attention to thrombosis and reticulin as key risks.

This article is for educational and research purposes only. Peptides discussed here are not approved for human consumption by the FDA, EMA, or equivalent regulators outside of specific clinical contexts. Always consult a licensed medical professional before any therapeutic use.